Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders' perspectives in Burkina Faso and Nigeria
- PMID: 36083995
- PMCID: PMC9462557
- DOI: 10.1371/journal.pone.0273249
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders' perspectives in Burkina Faso and Nigeria
Abstract
Background: Artemisinin-based combination therapies (ACTs) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in all malaria endemic countries. Artemisinin resistance, partner drug resistance, and subsequent ACT failure are widespread in Southeast Asia. The more recent independent emergence of artemisinin resistance in Africa is alarming. In response, triple artemisinin-based combination therapies (TACTs) are being developed to mitigate the risks associated with increasing drug resistance. Since ACTs are still effective in Africa, where malaria is mainly a paediatric disease, the potential deployment of TACTs raises important ethical questions. This paper presents an analysis of stakeholders' perspectives regarding key ethical considerations to be considered in the deployment of TACTs in Africa provided they are found to be safe, well-tolerated and effective for the treatment of uncomplicated malaria.
Methods: We conducted a qualitative study in Burkina Faso and Nigeria assessing stakeholders' (policy makers, suppliers and end-users) perspectives on ethical issues regarding the potential future deployment of TACTs through 68 in-depth interviews and 11 focus group discussions.
Findings: Some respondents suggested that there should be evidence of local artemisinin resistance before they consider deploying TACTs, while others suggested that TACTs should be deployed to protect the efficacy of current ACTs. Respondents suggested that additional side effects of TACTs compared to ACTs should be minimal and the cost of TACTs to end-users should not be higher than the cost of current ACTs. There was some disagreement among respondents regarding whether patients should have a choice of treatment options between ACTs and TACTs or only have TACTs available, while ACTs are still effective. The study also suggests that community, public and stakeholder engagement activities are essential to support the introduction and effective uptake of TACTs.
Conclusion: Addressing ethical issues regarding TACTs and engaging early with stakeholders will be important for their potential deployment in Africa.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?PLoS One. 2021 Aug 31;16(8):e0256567. doi: 10.1371/journal.pone.0256567. eCollection 2021. PLoS One. 2021. PMID: 34464398 Free PMC article.
-
Expert perspectives on the introduction of Triple Artemisinin-based Combination Therapies (TACTs) in Southeast Asia: a Delphi study.BMC Public Health. 2022 Apr 30;22(1):864. doi: 10.1186/s12889-022-13212-x. BMC Public Health. 2022. PMID: 35490212 Free PMC article.
-
Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.Wellcome Open Res. 2021 Apr 7;6:75. doi: 10.12688/wellcomeopenres.16065.1. eCollection 2021. Wellcome Open Res. 2021. PMID: 34458588 Free PMC article.
-
Triple Artemisinin-Based Combination Therapies for Malaria - A New Paradigm?Trends Parasitol. 2021 Jan;37(1):15-24. doi: 10.1016/j.pt.2020.09.011. Epub 2020 Oct 12. Trends Parasitol. 2021. PMID: 33060063 Review.
-
Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination.Parasite. 2018;25:24. doi: 10.1051/parasite/2018021. Epub 2018 Apr 20. Parasite. 2018. PMID: 29676250 Free PMC article. Review.
Cited by
-
Antiplasmodial potential of isolated xanthones from Mesua ferrea Linn. roots: an in vitro and in silico molecular docking and pharmacokinetics study.BMC Complement Med Ther. 2024 Jul 25;24(1):282. doi: 10.1186/s12906-024-04580-5. BMC Complement Med Ther. 2024. PMID: 39054443 Free PMC article.
-
A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria.Malar J. 2023 Jun 17;22(1):185. doi: 10.1186/s12936-023-04622-2. Malar J. 2023. PMID: 37330469 Free PMC article.
-
Artemisinin-resistant malaria.Clin Microbiol Rev. 2024 Dec 10;37(4):e0010924. doi: 10.1128/cmr.00109-24. Epub 2024 Oct 15. Clin Microbiol Rev. 2024. PMID: 39404268 Review.
-
Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts.Malar J. 2024 Jan 18;23(1):25. doi: 10.1186/s12936-024-04844-y. Malar J. 2024. PMID: 38238781 Free PMC article. Review.
-
Interventions to address antimicrobial resistance: an ethical analysis of key tensions and how they apply in low- income and middle-income countries.BMJ Glob Health. 2024 Apr 3;9(4):e012874. doi: 10.1136/bmjgh-2023-012874. BMJ Glob Health. 2024. PMID: 38569658 Free PMC article. Review.
References
-
- Brentlinger PE. Health, human rights, and malaria control: historical background and current challenges. Health Hum Rights. 2006;9(2):10–38. - PubMed
-
- World Health Organisation 2022. WHO Guidelines for Malaria 2022. Accessed 20th May 2022.
-
- Bosman A, Mendis KN. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg. 2007;77(6 Suppl):193–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
